Alzheimer’s disease
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
AB Science SA reported promising data from its Phase IIb/III trial of masitinib in patients with confirmed mild to moderate Alzheimer’s disease.
vTv Therapeutics, based in High Point, North Carolina, announced that its Phase II Elevage study of azeliragon in mild Alzheimer’s disease and type 2 diabetes failed to hit its primary objective.
Over a decade of research and billions of dollars have been poured into Alzheimer’s disease treatment. Experts are hopeful we could finally find a cure.
Jeff Dage, Ph.D., senior research adviser at Eli Lilly and Company, presented the case for P-tau in blood as an accurate biomarker.
Biogen and Tokyo-based development partner Eisai are embroiled in controversy surrounding their investigational Alzheimer’s drug, aducanumab.
The drug failed to meet its primary efficacy endpoint, as well as two secondary endpoints.
“We are grateful to the NIA for their rigorous scientific review and funding support to advance ALZ-8801 for Alzheimer’s patients in need of an effective treatment,” said Martin Tolar, founder, president and chief executive officer of Alzheon.
A study published in the Journal of the American Medical Association on July 29 now shows that a new blood test may be helpful for detecting Alzheimer’s disease as early as 20 years before the onset of cognitive impairment.
PRESS RELEASES